InjectionClinical Overview
Dacarbazine Injection (200mg) is an alkylating triazene antineoplastic on the WHO Model List of Essential Medicines. Following hepatic CYP1A bioactivation, it degrades to diazomethane and active 5-aminoimidazole-4-carboxamide (AIC), generating reactive methonium ions that alkylate DNA at O-6 and N-7 guanine positions. Indicated as a fundamental component of the ABVD regimen for Hodgkin lymphoma, metastatic malignant melanoma, and soft tissue sarcomas.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administer intravenously by slow infusion over 15 to 30 minutes diluted in 5% Dextrose or 0.9% NaCl. Protect solution from light during administration. Administer antiemetics beforehand (highly emetogenic).
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Severe acute nausea and vomiting (>90% of patients), bone marrow depression (leukopenia, thrombocytopenia nadir at 21-25 days), flu-like syndrome, alopecia, local burning/pain along the infusion vein. Rare/Severe: Hepatic vein thrombosis / hepatic necrosis (Budd-Chiari syndrome), anaphylaxis, and tissue necrosis upon extravasation.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Severe bone marrow suppression and hepatic necrosis with vascular thrombosis (fatal Budd-Chiari syndrome). Highly emetogenic; pre-medicate aggressively. Extravasation causes severe pain and tissue damage. Protect infusion line from direct sunlight.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.